Highlights Applied Genetic Technologies Corporation

Equities

AGTC

US03820J1007

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Syncona's Achilles says cancer treatment shows promise; seals buy	22-12-01	AN
British Investor Syncona Closes Acquisition of US Biotech Applied Genetic Technologies	22-12-01	MT
Syncona Limited, a fund managed by Syncona Investment Management Limited completed the acquisition of Applied Genetic Technologies Corporation.	22-11-29	CI
TOP NEWS: AstraZeneca to buy Neogene for cancer treatment	22-11-29	AN
Syncona Extends Offer Period For $24 Million Takeover of Applied Genetic Technologies	22-11-29	MT
Applied Genetic Technologies Corporation Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-21	CI
Applied Genetic Technologies Shares Soar After Company Agrees to Sell to Syncona for $23.5 Million	22-10-24	MT
ETF Preview: ETFs, Futures Rising Pre-Bell After Chicago Fed National Activity Index Report	22-10-24	MT
Applied Genetic Technologies Agrees to Sell to Syncona for $23.5 Million Through Tender Offer	22-10-24	MT
Syncona to acquire retinal therapy firm Applied Genetic Technologies	22-10-24	AN
Syncona To Launch $24 Million Takeover Offer For Applied Genetic Technologies	22-10-24	MT
Syncona Limited, a fund managed by Syncona Investment Management Limited, entered into a definitive agreement to acquire Applied Genetic Technologies Corporation for $23.3 million.	22-10-23	CI
Applied Genetic Technologies Corporation Reports Earnings Results for the Full Year Ended June 30, 2022	22-09-27	CI
AGTC Receives Positive Type C Meeting Feedback from the Fda for the Company's Design and Operating Procedures of Its Planned cGMP Manufacturing Facility	22-07-26	CI
Applied Genetic Technologies Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	22-05-16	CI
AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa	22-05-16	CI
Applied Genetic Technologies Corporation Presents Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 At the Association for Research in Vision and Ophthalmology 2022 Annual Meeting	22-05-04	CI
Applied Genetic Technologies Corporation Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	22-02-14	CI
Applied Genetic Technologies Reports Updated Interim Three-Month Pediatric Results and Additional Adult Safety Results Out to as Long as 24 Months from Its Ongoing Phase 1/2 Dose Escalation Study of AGTC-401	22-02-08	CI
AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa	22-01-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Applied Genetic Technologies Corporation

Equities

AGTC

US03820J1007

Highlights

Filters